Another ISPOR International in the books! After staying close to home in Boston last year, it was great to have a change of scene in Atlanta, allowing us to try 40+ flavours of Coca-Cola and watch sharks and rays at the Georgia Aquarium! However, once the sugar rush subsided, the core of the trip remained the same as previous conferences: striving for professional growth and (re)connecting with clients and other fellow HEOR enthusiasts to make the most of our time away from our desks.
Costello Medical had an incredibly successful trip, with our nine delegates across our Evidence Development, Market Access, Health Economics, Rare Diseases and MedTech teams thoroughly enjoying engaging with impactful research and sessions, the opportunities for networking, and insightful conversations held at our company booth.
The agenda was a mix of sessions building on well-known topics from previous ISPORs such as the use of artificial intelligence (AI) in HEOR, the impact of the Inflation reduction Act (IRA) and real-world evidence (RWE), in addition to more novel subject matter, particularly on new methodologies and frameworks in the digital health, statistics and health economics space. In line with our reflections from ISPOR EU last year, it was again apparent that some of these hot topics have entered a phase of implementation, feedback gathering and learning from experience, rather than focussing solely on theoretical applications.
There was, of course, plenty more on the conference agenda besides the above topics across many different session formats. We were pleased to contribute six research posters of our own including a comparison of prescription drug affordability boards (PDABs) across the US that was selected for a poster tour as well as a case study exploring piecewise modelling in oncology that was selected as “Best New Investigator Poster Research Presentation” for the conference (please see here for these and our other published research). We were also delighted to present a number of posters on behalf of our clients.
Our conference delegates have prepared commentaries on a variety of specific topics from the conference at the following links. We hope you enjoy reading them!
Advancing Statistical Methods: Innovations at ISPOR 2024
From Promise to Practice: The Evolving Role of GenAI in HEOR
Ignorance is not Bliss: The Value of Diagnostics in the Absence of Optimal Therapies
IRA and US Drug Price Negotiations
Overcoming Hesitancy to Include Real-World Evidence (RWE) in Reimbursement Submissions
To Incentivise a “Whole Health” Approach, We Need to Fix the “Wrong Pocket Problem”
What’s this Button for? Digital Health is Being Held to a Higher Standard
If you would like any further information about our presence at ISPOR International 2024 and learnings from attending the conference, please do not hesitate to contact Molly Atkinson, US Head of Market Access and Health Economics (LinkedIn).
